Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. - Wikidata - awgldk - TriplyDB

Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations.

Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations.

http://www.wikidata.org/entity/Q40055172

about

Role of LOX-1 and ROS in oxidized low-density lipoprotein induced epithelial-mesenchymal transition of NRK52E Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation.Renal lipid metabolism and lipotoxicity.Chronic effects of aerobic exercise on gene expression of LOX-1 receptor in the heart of rats fed with high fat diet Comprehensive genomic profiling in diabetic nephropathy reveals the predominance of proinflammatory pathways.Electronegative low density lipoprotein induces renal apoptosis and fibrosis: STRA6 signaling involved.Hyperlipidemia: a new therapeutic target for diabetic neuropathy.LOX-1: a new target for therapy for cardiovascular diseases.LOX-1: a critical player in the genesis and progression of myocardial ischemia.LOX-1 and angiotensin receptors, and their interplay.LOX-1 and obesity.LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications.Renal iron overload in rats with diabetic nephropathy.LOX-1-Targeted Iron Oxide Nanoparticles Detect Early Diabetic Nephropathy in db/db Mice.The variability of oxLDL-induced cytotoxicity on different types of cell lines.LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes.Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy.Postischemic inflammatory syndrome: a critical mechanism of progression in diabetic nephropathy.Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling.A review of molecular imaging of atherosclerosis and the potential application of dendrimer in imaging of plaque.

P2860

Q30990551-7E5ABC3D-E38F-404B-A3FF-93E1268F3C49 Q33710962-DE0C02D6-54FC-4115-8723-877D0D8CBFD1 Q34825296-1FD9EDA0-DDF8-43D0-A39B-43B24141491E Q36249346-873A24BB-DEDD-4E03-A979-17F78B856D70 Q37093818-2AD904A9-7E7A-479C-BC79-17F540F359E9 Q37123819-421913D9-4A40-42D7-9DAA-1AB284F38F99 Q37659233-54770BF0-8546-4098-A414-A70321BA28EF Q37914024-C09EC2B4-55E7-4774-A490-C4EFFF38C373 Q37918860-67327EF4-B3AA-4294-B58D-A78BD876B0B7 Q37921158-CB200893-9EFD-43B5-A66B-7CB9BE16A034 Q37924630-7F4AA5BB-2EEF-4C7F-98D2-574A89818F29 Q37945097-E592B789-CB9A-4BC9-BB05-E63FD2FAF1E6 Q38565776-F0D57D3C-56D4-4840-BE7C-9330EE2C0287 Q38911361-3DDF6C38-E99A-42CB-84B8-B519251FF336 Q39182530-14F3876E-1C34-4B39-A99A-028B5545EFEA Q40005574-A33EFF87-6169-441E-AB9A-E3576A06A22F Q43064230-001599B4-D587-4E56-9A6F-D214538124BC Q45769086-8EAE2C8A-A30C-4881-9D2B-2CAD7FF56EB8 Q47194713-13C526CB-39D2-4DEB-9D3A-F00131F0B713 Q47866518-345055DA-14C8-4207-B8D7-FF7E91B492FA

P2860

Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations.

http://www.wikidata.org/entity/Q40055172

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Anti-LOX-1 therapy in rats wit ...... and epithelial manifestations.

@en

type

label

Anti-LOX-1 therapy in rats wit ...... and epithelial manifestations.

@en

prefLabel

Anti-LOX-1 therapy in rats wit ...... and epithelial manifestations.

@en

P1433

Q40055172-E91671B2-198C-4DE8-B94C-0796EE508CDB

P1476

Q40055172-D893DCBF-74F5-4BC0-99FD-76A3768B8D3E

P2093

Q40055172-168D4439-A4EF-4FBE-8D6E-CB7189A16796

Q40055172-2093A343-F954-4B2D-9CAD-B0AFA25F5232

Q40055172-21DC13AF-DE4B-423D-8900-339550022DEF

Q40055172-2AE1F3A3-D565-4530-8B74-C27D2B7E017A

Q40055172-2BBE2A8A-85A4-431A-A099-464C19042B54

Q40055172-5EF536E6-D268-4456-A6FA-47DE13BE9B92

Q40055172-62AB5A22-135C-444E-BF89-4609A1CEAD44

Q40055172-75867E94-4ABE-41F5-8E83-04704CBDF584

Q40055172-7673BBCF-E2C5-4A69-AE33-12333483AEB7

Q40055172-7D683F6E-97B6-460E-BF0F-BEED856B4FA5

P2860

Q40055172-188AF37C-686C-4B5D-A4C8-370B677ED913

Q40055172-19601360-81FE-412B-8690-989061415396

Q40055172-1F83B08C-28A7-40BE-BA96-172DBC5EE48C

Q40055172-2AABFA8E-065C-41DA-BF5E-683B6C7C74FA

Q40055172-37F44212-31A5-4BFA-8D45-DFAA8D829527

Q40055172-42A2AEC7-0C4F-46BE-AD28-C2FF5E5A7061

Q40055172-4602501F-D921-466E-AD26-B322AAD9BA9F

Q40055172-491EB598-FC6C-4C1F-937E-4CF27B5CE59C

Q40055172-4DE9D916-8AA8-4AF3-99F8-2FF8BA174BDE

Q40055172-4E8B7405-30A2-4E98-B73F-D19026B5EFA3

P304

Q40055172-A92526C7-ACF2-424E-9DE6-5B17254B22BB

P31

Q40055172-E3CE16D2-ED37-478E-B976-E81438667D8B

P356

Q40055172-D7FF0900-1FD9-4F58-B2D8-A12DDE796C17

P433

Q40055172-A2475CC2-E367-4213-8A90-57D75B63D69B

P478

Q40055172-5DB87341-7BBD-4B90-8760-F6EFC0030AF5

P577

Q40055172-2E20EEC8-39F0-4658-9F51-CE77EE8B251B

P5875

Q40055172-D558A2B1-6681-4AD1-8B01-83F0263E2F8C

P698

Q40055172-304DD53D-861F-4523-BDC5-184B3FF25F2E

P921

Q40055172-2253BF77-2CF7-40C3-B6EE-0D0B767C2A74

P356

AJPRENAL.00013.2007

P1433

American Journal of Physiology - Renal Physiology

P1476

Anti-LOX-1 therapy in rats wit ...... and epithelial manifestations.

@en

P2093

C Subah Packer

http://www.w3.org/2001/XMLSchema#string

Carolyn E Patterson

http://www.w3.org/2001/XMLSchema#string

Constance Temm

http://www.w3.org/2001/XMLSchema#string

Dayuan Li

http://www.w3.org/2001/XMLSchema#string

Erin Goss

http://www.w3.org/2001/XMLSchema#string

Jawahar L Mehta

http://www.w3.org/2001/XMLSchema#string

Jesus H Dominguez

http://www.w3.org/2001/XMLSchema#string

John W Hawes

http://www.w3.org/2001/XMLSchema#string

Katherine J Kelly

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

An endothelial receptor for oxidized low-density lipoprotein

Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding

Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation

The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide

Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes

The human gene encoding the lectin-type oxidized LDL receptor (OLR1) is a novel member of the natural killer gene complex with a unique expression profile

A general model for the origin of allometric scaling laws in biology

Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation

Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder.

Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders.

P304

F110-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00013.2007

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

294

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5857838

http://www.w3.org/2001/XMLSchema#string

P698

17989113

http://www.w3.org/2001/XMLSchema#string

P921